Teladoc Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Teladoc Health, Inc. on August 27, 2026, reporting events occurring on August 27 and August 31, 2026. The filing primarily addresses the appointment of a new Chief Financial Officer (CFO) and the associated compensatory arrangements.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
Material Changes
- Executive Appointment: Michael Grasher was hired as Chief Financial Officer, effective August 31, 2026.
- Leadership Continuity: Charles Divita, III, who served as interim principal financial officer, will continue as Chief Executive Officer.
Compensation, Outlook, and Risks
Compensatory Arrangements:
- Base Salary: $550,000 annually.
- Sign-on Bonus: One-time payment of $500,000.
- Annual Bonus: Targeted at 85% of base salary, commencing in 2027.
- Equity Incentive: A new-hire award with a target value of approximately $3,000,000, issued as 50% Restricted Stock Units (RSUs) and 50% Performance Stock Units (PSUs).
Performance Metrics: The PSUs are tied to:
- Adjusted EBITDA for 2026.
- Compound Annual Revenue Growth Rate (CAGR) from January 1, 2026, through December 31, 2028.
Severance Provisions:
- Standard Termination: 12 months of base salary, pro-rated bonus, and accelerated vesting of service-based equity.
- Change of Control Termination: 18 months of base salary, 100% of target bonus, and full acceleration of unvested service-based equity.
Risks and Contingencies: The filing notes standard non-compete and non-solicitation provisions for 12 months post-employment. No other material risks or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the exact vesting schedule and performance thresholds for the $3,000,000 equity award in the attached Offer Letter (Exhibit 10.1).
- Review the definitions of "cause," "good reason," and "change of control" in the Employment Agreement (Exhibit 10.2) to understand severance triggers.
- Confirm the impact of the new CFO's appointment on the company's strategic financial planning and reporting timeline.
- Check subsequent filings for the actual issuance date of the equity awards (expected September 1, 2026).